John E Levine

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy
    John E Levine
    Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan 48109 0914, USA
    Biol Blood Marrow Transplant 9:189-97. 2003
  2. ncbi Clinical applications for biomarkers of acute and chronic graft-versus-host disease
    John E Levine
    Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan 48109 5941, USA
    Biol Blood Marrow Transplant 18:S116-24. 2012
  3. ncbi Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation
    John E Levine
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 20:405-12. 2002
  4. ncbi Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease
    John E Levine
    Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA
    Blood 111:2470-5. 2008
  5. ncbi Graft-versus-host disease treatment: predictors of survival
    John E Levine
    Departments of Pediatrics and Internal Medicine, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109 5941, USA
    Biol Blood Marrow Transplant 16:1693-9. 2010
  6. ncbi Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT)
    John E Levine
    Department of Pediatrics, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan 48109 5941, USA
    Biol Blood Marrow Transplant 14:1017-21. 2008
  7. ncbi Clinical applications of hematopoietic growth factors in pediatric oncology
    John E Levine
    Division of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, Michigan 48109 0914, USA
    Curr Opin Hematol 9:222-7. 2002
  8. ncbi TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes
    Sung W Choi
    Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI 48109 5942, USA
    Biol Blood Marrow Transplant 18:1525-32. 2012
  9. ncbi Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients
    Carrie L Kitko
    Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Biol Blood Marrow Transplant 14:759-65. 2008
  10. ncbi Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation
    Gregory A Yanik
    Blood and Marrow Stem Cell Transplantation Program, Division of Hematology Oncology, Department of Pediatrics, University of Michigan Medical Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Biol Blood Marrow Transplant 18:1044-54. 2012

Research Grants

  1. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2006

Detail Information

Publications41

  1. ncbi Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy
    John E Levine
    Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan 48109 0914, USA
    Biol Blood Marrow Transplant 9:189-97. 2003
    ..A reduction in conditioning intensity is associated with poor survival for patients with advanced-stage disease, highlighting the importance of the conditioning regimen for tumor control...
  2. ncbi Clinical applications for biomarkers of acute and chronic graft-versus-host disease
    John E Levine
    Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan 48109 5941, USA
    Biol Blood Marrow Transplant 18:S116-24. 2012
    ..The utility of GVHD biomarkers in clinical care of allogeneic hematopoietic cell transplantation recipients needs to be proven through clinical trials, and potential approaches to trial design are discussed...
  3. ncbi Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation
    John E Levine
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 20:405-12. 2002
    ..A chemotherapy strategy was used to debulk disease before administration of granulocyte colony-stimulating factor (G-CSF)-primed DLIs...
  4. ncbi Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease
    John E Levine
    Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA
    Blood 111:2470-5. 2008
    ..We conclude that etanercept plus steroids as initial therapy for acute GVHD results in a substantial majority of CRs. This trial was referenced at www.clinicaltrials.gov as NCT00141713...
  5. ncbi Graft-versus-host disease treatment: predictors of survival
    John E Levine
    Departments of Pediatrics and Internal Medicine, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109 5941, USA
    Biol Blood Marrow Transplant 16:1693-9. 2010
    ..If verified as a reliable predictor of late outcomes following other aGVHD treatment approaches, day 28 response should serve as a standard early endpoint for future trials of aGVHD therapy...
  6. ncbi Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT)
    John E Levine
    Department of Pediatrics, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan 48109 5941, USA
    Biol Blood Marrow Transplant 14:1017-21. 2008
    ..We conclude that the benefits of palifermin appear primarily to be limited to ameliorating mucotoxicity when given to allogeneic HCT recipients...
  7. ncbi Clinical applications of hematopoietic growth factors in pediatric oncology
    John E Levine
    Division of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, Michigan 48109 0914, USA
    Curr Opin Hematol 9:222-7. 2002
    ....
  8. ncbi TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes
    Sung W Choi
    Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI 48109 5942, USA
    Biol Blood Marrow Transplant 18:1525-32. 2012
    ..These findings suggest that (1) the effectiveness of TNF-inhibition with etanercept may depend on the conditioning regimen, and (2) attenuating the expected rise in TNFR1 levels early posttransplantation correlates with good outcomes...
  9. ncbi Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients
    Carrie L Kitko
    Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Biol Blood Marrow Transplant 14:759-65. 2008
    ..However, increases in the concentration of TNFR1, which are detectable up to 2 weeks in advance of clinical manifestations of GVHD, correlate with survival in pediatric HCT patients...
  10. ncbi Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation
    Gregory A Yanik
    Blood and Marrow Stem Cell Transplantation Program, Division of Hematology Oncology, Department of Pediatrics, University of Michigan Medical Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Biol Blood Marrow Transplant 18:1044-54. 2012
    ..These data support the development of expanded clinical trials to study etanercept as a therapeutic agent for subacute lung injury after allogeneic stem cell transplantation...
  11. ncbi Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study
    John E Levine
    University of Michigan Blood and Marrow Transplant Program, Ann Arbor, USA
    Blood 119:3854-60. 2012
    ..The study was registered in clinicaltrials.gov as NCT00224874...
  12. ncbi A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study
    M Fevzi Ozkaynak
    Department of Pediatrics, Section of Hematology Oncology, New York Medical College, Valhalla, NY 10595, USA
    J Pediatr Hematol Oncol 30:204-9. 2008
    ..i.d. for 4 days can be administered with a double alkylator regimen consisting of melphalan (200 mg/m), cyclophosphamide (up to 3800 mg/m), carboplatin (1200 mg/m), and etoposide (800 mg/m) with manageable toxicities...
  13. ncbi Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival
    Sung W Choi
    Department of Pediatrics, Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI 48109 5942, USA
    Blood 112:1539-42. 2008
    ..Measurement of TNFR1 levels early after transplantation provides independent information in advance of important clinical outcomes, such as GVHD and death...
  14. ncbi Plasma biomarkers of lower gastrointestinal and liver acute GVHD
    Andrew C Harris
    Blood and Marrow Transplant Program, The University of Michigan, Ann Arbor, MI 48109 5942, USA
    Blood 119:2960-3. 2012
    ..02, respectively). Liver GVHD without GI involvement at GVHD onset and non-GVHD liver complications were uncommon; all 3 biomarkers were elevated in liver GVHD, but did not distinguish GVHD from other causes of hyperbilirubinemia...
  15. ncbi Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease
    Joseph P Uberti
    Department of Internal Medicine, Blood and Marrow Stem Cell Transplantation Program, University of Michigan, Ann Arbor, USA
    Biol Blood Marrow Transplant 11:680-7. 2005
    ..In contrast, for 15 responding patients, soluble TNF receptor 1 plasma concentration levels returned to baseline. These data demonstrate the feasibility of using cytokine blockade in the early treatment of aGVHD...
  16. ncbi Graft-versus-host disease
    James L M Ferrara
    University of Michigan, Pediatrics and Internal Medicine, Blood and Marrow Transplantation Program, Ann Arbor, MI 48109 5942, USA
    Lancet 373:1550-61. 2009
    ..We also summarise supportive-care measures that are essential for management of this medically fragile population...
  17. ncbi A biomarker panel for acute graft-versus-host disease
    Sophie Paczesny
    Department of Pediatrics, University of Michigan, Ann Arbor, USA
    Blood 113:273-8. 2009
    ..A panel of 4 biomarkers can confirm the diagnosis of GVHD in patients at onset of clinical symptoms of GVHD and provide prognostic information independent of GVHD severity...
  18. ncbi The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation
    Gregory A Yanik
    Department of Pediatrics, University of Michigan, Ann Arbor, USA
    Blood 112:3073-81. 2008
    ..The combination of etanercept and corticosteroids is safe and is associated with high response rates and improved survival in patients with IPS...
  19. ncbi Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease
    James L M Ferrara
    Department of Pediatrics, University of Michigan, Ann Arbor, MI 48109, USA
    Blood 118:6702-8. 2011
    ..001). REG3α is a plasma biomarker of GI GVHD that can be combined with clinical stage and histologic grade to improve risk stratification of patients...
  20. ncbi Pathogenesis and management of graft-versus-host disease
    Sung W Choi
    Department of Pediatrics, Blood and Marrow Transplant Program, University of Michigan Medical School, 1500 E Medical Center Drive, 6303 Comprehensive Cancer Center, Ann Arbor, MI 48109 5942, USA
    Immunol Allergy Clin North Am 30:75-101. 2010
    ....
  21. ncbi Plasma biomarkers in graft-versus-host disease: a new era?
    Sophie Paczesny
    Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA
    Biol Blood Marrow Transplant 15:33-8. 2009
    ..If successful, these studies could establish a novel biomarker panel that will contribute important information including long term survival, and that may eventually facilitate therapeutic decisions for allogeneic HCT patients...
  22. ncbi Successful treatment of refractory immune hemolysis following unrelated cord blood transplant with Campath-1H
    Mwe Mwe Chao
    Department of Pediatrics, Division of Pediatric Hematology Oncology and Blood and Marrow Transplantation, University of Michigan Health System, Ann Arbor, Michigan, USA
    Pediatr Blood Cancer 50:917-9. 2008
    ..The case also emphasizes the importance of T-cells in transplant associated immune cytopenias...
  23. ncbi Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes
    Andrew C Harris
    Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI, USA
    Haematologica 98:179-84. 2013
    ..Effective strategies for patients with extramedullary relapse are needed to improve outcomes after transplantation...
  24. ncbi Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease
    Mark C Walters
    Blood and Marrow Transplantation Program, Children s Hospital and Research Center, Oakland, California 94609, USA
    Biol Blood Marrow Transplant 16:263-72. 2010
    ..In summary, individuals who had stable donor engraftment did not experience sickle-related complications after BMT, and were protected from progressive CNS and pulmonary disease...
  25. ncbi A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma
    John E Levine
    University of Michigan Medical Center, Ann Arbor, USA
    Blood 101:2476-82. 2003
    ..In summary, alloSC transplantation for LBL is associated with fewer relapses than with autoSC transplantation, but higher TRM offsets any potential survival benefit...
  26. ncbi Elafin is a biomarker of graft-versus-host disease of the skin
    Sophie Paczesny
    Department of Pediatrics, University of Michigan, Ann Arbor, MI 48109, USA
    Sci Transl Med 2:13ra2. 2010
    ..78). We conclude that elafin has significant diagnostic and prognostic value as a biomarker of skin GVHD...
  27. ncbi Implications of TNF-α in the pathogenesis and management of GVHD
    John E Levine
    University of Michigan Blood and Marrow Transplantation Program, 5303 Cancer Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109 5941, USA
    Int J Hematol 93:571-7. 2011
    ..TNF-α can be pharmacologically inhibited using soluble TNF receptors or monoclonal antibodies. The optimal dosing and duration of TNF inhibition to prevent or treat GVHD remains under investigation...
  28. ncbi A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study
    Haydar Frangoul
    Department of Pediatrics, Vanderbilt University, Nashville, TN 37232 2573, USA
    Blood 110:4584-7. 2007
    ..Collection of G-BM from pediatric donors is safe, and can result in high NC and CD34 cell doses that facilitate engraftment after myeloablative BMT without a discernable increase in the risk of GVHD...
  29. ncbi Malignant triton tumor in a patient with Li-Fraumeni syndrome and a novel TP53 mutation
    Mwe Mwe Chao
    Department of Pediatric Hematology Oncology and Bone Marrow Transplantation, University of Michigan Health System, Ann Arbor, Michigan 48109 0914, USA
    Pediatr Blood Cancer 49:1000-4. 2007
    ..The tumor could not be resected and he was successfully treated with intensive induction chemotherapy, irradiation, and high-dose chemotherapy with autologous stem cell transplantation...
  30. ncbi Graft-versus-host disease in the 21st century: new perspectives on an old problem
    James L M Ferrara
    University of Michigan Medical School, Ann Arbor, MI, USA
    Semin Hematol 43:1-2. 2006
  31. ncbi Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007
    James L M Ferrara
    University of Michigan, Ann Arbor, Michigan, USA
    Biol Blood Marrow Transplant 13:1268-85. 2007
    ..This report summarizes the symposium's discussions and identifies eleven high priority clinical trials that the network plans to pursue over the course of the next several years...
  32. ncbi Hematopoietic stem cell transplantation for severe congenital neutropenia
    James A Connelly
    Division of Pediatric Hematology Oncology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Curr Opin Hematol 19:44-51. 2012
    ..This review focuses on recent advancements in risk stratification of SCN patients, indications for HCT, and review of published transplant studies...
  33. ncbi Successful unrelated donor cord blood transplantation for Glanzmann's thrombasthenia
    Carrie L Kitko
    Department of Pediatrics and Internal Medicine, Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI, USA
    Pediatr Transplant 15:e42-6. 2011
    ....
  34. ncbi Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease
    John M Magenau
    Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA
    Biol Blood Marrow Transplant 16:907-14. 2010
    ..03). Treg frequency may therefore have important prognostic value as a biomarker of aGVHD...
  35. ncbi Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma
    Gregory A Yanik
    Blood and Marrow Stem Cell Transplantation Program, Division of Pediatric Hematology Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    J Clin Oncol 20:2142-9. 2002
    ..A pilot study was performed to examine the feasibility of a novel regimen combining (131)I-MIBG and myeloablative chemotherapy with autologous stem-cell rescue...
  36. ncbi Advances in predicting acute GVHD
    Andrew C Harris
    Blood and Marrow Transplant Program, Department of Pediatrics, C S Mott Children s Hospital, University of Michigan, Ann Arbor, MI 48109, USA
    Br J Haematol 160:288-302. 2013
    ....
  37. ncbi Have we made progress in the treatment of GVHD?
    Andrew C Harris
    University of Michigan Medical School, 6303 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 4810, USA
    Best Pract Res Clin Haematol 25:473-8. 2012
    ....
  38. ncbi Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM
    Thomas M Braun
    Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan 48109 2029, USA
    Control Clin Trials 24:669-81. 2003
    ..Our simulations are based upon a study in bone marrow transplant patients that seeks to determine how many weeks of recombinant human keratinocyte growth factor can be administered while keeping toxicity rates below a desired threshold...
  39. ncbi Utility of cranial boost in addition to total body irradiation in the treatment of high risk acute lymphoblastic leukemia
    Brian M Alexander
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109-0010, USA
    Int J Radiat Oncol Biol Phys 63:1191-6. 2005
    ....
  40. ncbi Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee
    Stephan A Grupp
    Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 46:414-21. 2006
    ..We conclude that the approach is promising and warrants further study. Risks of G-CSF to the donor are minimal and benefits to both donor and recipient may occur...
  41. ncbi Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion
    David Porter
    Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Semin Hematol 43:53-61. 2006
    ..Strategies to reduce the incidence and severity of GVHD while preserving the graft-versus-leukemia (GVL) effect, such as low-dose DLI, depletion of GVHD effector cells, and tumor-specific DLI, are reviewed...

Research Grants1

  1. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2006
    ..2A. To evaluate a panel of cytokines as surrogate markers for GVHD and correlate these with clinical outcomes during the above trial. 2B. To correlate changes in minimal residual disease with clinical outcomes during the above trial. ..